Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
– Interim update from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) to be presented at the ESMO Immuno-Oncology Annual Congress 2022 –
Related news for (ACHL)
- 24/7 Market News- Achilles Therapeutics Discontinues TIL-based cNeT Therapy Development to Focus on Third Party Target
- Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
- Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
- Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights
- Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference